免疫联合治疗提升抗肿瘤疗效
本综述评估了可识别单药免疫治疗获益人群的生物标志物,并系统回顾了免疫联合化疗、靶向治疗、放疗、瘤内治疗、其他免疫调节剂及过继细胞治疗等策略的原理,提出需建立生物标志物驱动的联合治疗选择框架。
要点
- 免疫检查点抑制剂对多种肿瘤有效,但部分患者无应答或获益不持久。
- 生物标志物可区分单药获益人群,避免不必要的联合治疗。
- 联合治疗策略多样,需程序化框架指导生物标志物驱动的选择。
核心结论
- 免疫联合治疗是克服原发性和获得性耐药、增强疗效的重要方向,但需生物标志物驱动选择。
研究设计与样本
- 本综述评估免疫治疗应答生物标志物,并回顾联合治疗策略的原理与进展。
主要发现
- 免疫检查点抑制剂已获监管批准用于多种肿瘤,但许多患者不应答或获益不持久。
- 联合策略包括化疗、靶向治疗、放疗、瘤内治疗、其他免疫调节剂及过继细胞治疗。
- 过继细胞治疗包括嵌合抗原T细胞受体及其他新型T细胞受体疗法。
临床怎么用
- 临床可依据生物标志物识别单药免疫治疗可能获益的患者,避免盲目联合。
- 联合治疗选择应纳入程序化框架,结合生物标志物进行决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several tumour types are responsive to immunotherapy, as shown by regulatory approvals for immune checkpoint inhibitors. However, many patients either do not respond or do not have durable clinical benefit. Thus, there is great interest in developing predictors of response to immunotherapy and rational combination therapies that can enhance efficacy by overcoming primary and acquired resistance. In this Review, we provide an assessment of immunotherapy response biomarkers that can identify patients who will benefit from monotherapy rather than from combinations. We review the rationale for combination therapy and different strategies, including combinations with chemotherapy, targeted therapy, radiation therapy, intratumoural therapies, other immunomodulators, and adaptive cell therapy, including chimeric antigen T-cell receptors and other novel T-cell receptor-based therapies. There are many combination partners in development; therefore, a programmatic approach is needed to develop a framework for biomarker-driven combination therapy selection.
引用
- Meric-Bernstam F, Larkin J, Tabernero J, et al. Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet. 2020. PMID: 33285141. doi:10.1016/S0140-6736(20)32598-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。